Full Generic Medicine Info
Dosage/Direction for Use

Opioid dependence
Adult: As hydrochloride: Initially, 25 mg; increase to 50 mg daily if no withdrawal signs occur. Maintenance: 350 mg wkly given as 50 mg daily or divided in 3 doses (given on 3 days of the wk) for improved compliance.

Adjunct in alcohol dependence
Adult: As hydrochloride: 50 mg daily.
May be taken with or without food.
Patients concurrently dependent on opioids; acute hepatitis or hepatic failure; acute opioid withdrawal; patients on therapeutic opioid analgesics.
Special Precautions
Hepatic or renal impairment. Monitor LFTs regularly. Patients should be opioid-free for at least 7-10 days prior to initiating naltrexone therapy. Strictly warn patients against the use of opioids while on naltrexone. Monitor for inj-site reactions. Pregnancy, lactation. History of bleeding disorders (including thrombocytopenia).
Adverse Reactions
Abdominal pain, nausea, vomiting; anxiety, insomnia, lethargy, headache, musculoskeletal pain; anorexia, diarrhoea, constipation; increased thirst; chest pain; chills, dizziness; sexual dysfunction; rash, liver function abnormalities and reversible idiopathic thrombocytopenia. Inj-site reactions.
Symptoms: Clonic-tonic convulsions and respiratory failure. Management: Supportive and symptomatic.
Drug Interactions
May reduce effects of opiate-containing preparations e.g. those used for cough and cold, diarrhoea and pain. Increased or decreased serum levels with drugs that alter hepatic metabolism. Potentially increased hepatotoxic effects with disulfiram. Increased risk of naltrexone-induced lethargy and somnolence with thioridazine. May increase insulin requirements.
Lab Interference
May interfere in the detection of urinary opiates using some immunoassay or enzymatic methods.
Naltrexone acts as a competitive antagonist at opioid receptor sites. It blocks the action of opioids and precipitates withdrawal symptoms in opioid-dependent individuals.
Absorption: Well absorbed from the GI tract. Peak plasma concentrations after about 1 hr.
Distribution: 20% bound to plasma proteins.
Metabolism: Extensively metabolised in the lvier. Undergoes considerable 1st-pass metabolism and may undergo enterohepatic recycling.
Excretion: Via urine (as <1% unchanged drug and as metabolites). Elimination half-life: Approx 4 hr.
Oral: Store at 20-25°C (68-77°F).
CIMS Class
Antidotes, Detoxifying Agents & Drugs Used in Substance Dependence
ATC Classification
N07BB04 - naltrexone ; Belongs to the class of drugs used in the management of alcohol dependence.
Disclaimer: This information is independently developed by CIMS based on naltrexone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in